In:
Cancer Research, American Association for Cancer Research (AACR), Vol. 74, No. 19_Supplement ( 2014-10-01), p. 1863-1863
Abstract:
Recent evidence suggests that genetic variations within the androgen receptor (AR) may influence the formation of TMPRSS2:ETS gene fusions, which are detected in more than half of all prostate cancers. We investigated the association between the length of the polymorphic trinucleotide CAG microsatellite repeats in exon 1 of the AR gene and risk of prostate cancer containing these fusion genes. This nested case-control study came from subjects enrolled in the Prostate Cancer Prevention Trial and included 195 biopsy-proven prostate cancer cases with known TMPRSS2:ETS status and 1344 matched controls. There was no association between CAG repeat length and risk of TMPRSS2:ETS-positive (OR=0.97, 95% CI, 0.91-1.04) or TMPRSS2:ETS-negative prostate cancer (OR=1.04, 95% CI, 0.97-1.10) and in patients with low- or high-grade disease. Our findings suggested that AR CAG repeats are not associated with TMPRSS2:ETS formation in prostate cancer. Citation Format: Douglas K. Price, Cindy H. Chau, William D. Figg, Catherine A. Till, Phyllis J. Goodman, Yonggon Cho, Marileila Garcia, Juergen Reichardt, Catherine M. Tangen, Robin J. Leach, Adrie van Bokhoven, Alan R. Kristal, Ian M. Thompson, M Scott Lucia. Androgen receptor CAG repeat length and TMPRSS2:ETS prostate cancer risk: results from the Prostate Cancer Prevention Trial. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 1863. doi:10.1158/1538-7445.AM2014-1863
Type of Medium:
Online Resource
ISSN:
0008-5472
,
1538-7445
DOI:
10.1158/1538-7445.AM2014-1863
Language:
English
Publisher:
American Association for Cancer Research (AACR)
Publication Date:
2014
detail.hit.zdb_id:
2036785-5
detail.hit.zdb_id:
1432-1
detail.hit.zdb_id:
410466-3